Skip to content

Incyte INCY Total Liabilities

Total Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$65.32B-15.4%
Pfizer logo
PfizerPFE
$3.41B-97.1%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$55.03M+50.8%
Geron logo
GeronGERN
$129.77M
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$41.99M-20.9%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$431.05M+1.3%

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$25.96B+73.3%
Enterprise value$22.01B+68.5%
P/E16.1×-1.1×
P/S4.5×+1.2×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Incyte’s 10-Q, filed July 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Incyte's total liabilities?
Incyte (INCY) reported total liabilities of $1.53B in Q2 2026.
How has Incyte's total liabilities changed year-over-year?
Incyte's total liabilities decreased by 7.4% year-over-year, from $1.65B to $1.53B.
What is the long-term trend for Incyte's total liabilities?
Over 5 years (2020 to 2025), Incyte's total liabilities has grown at a 13.5% compound annual growth rate (CAGR), from $949.65M to $1.79B.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.